KeywordsANA, antinuclear antibody
DILE, drug-induced lupus erythematosus
SCLE, subacute cutaneous lupus erythematosus
SLE, systemic lupus erythematosus
TNF, tumor necrosis factor
adverse drug reaction
drug induced lupus
subacute cutaneous lupus
SYSTEMIC LUPUS ERYTHEMATOSUS
DRUG-INDUCED LUPUS ERYTHEMATOSUS
MetadataShow full item record
PublisherJAAD Case Reports
JournalJAAD Case Reports
AbstractDrug-induced lupus erythematosus (DILE) is a lupus-like syndrome temporally related to continuous drug exposure. DILE can be divided into systemic lupus erythematosus (SLE), subacute cutaneous lupus erythematosus (SCLE) and chronic cutaneous lupus.1 Hydrochlorothiazide was the first drug associated with SCLE in 1985,2 but at least 100 other agents have since been reported to induce/exacerbate SCLE, with terbinafine, tumor necrosis factor (TNF)-α inhibitors, antiepileptics, and proton pump inhibitors, the most frequently associated medications. We present a case of ustekinumab-induced SCLE in a patient being treated for psoriasis.
The following license files are associated with this item:
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 United States
- Drug-Induced Lupus Erythematosus
- Authors: Solhjoo M, Ho CH, Chauhan K
- Issue date: 2019 Jan
- Drug-induced lupus: an update on its dermatologic aspects.
- Authors: Marzano AV, Vezzoli P, Crosti C
- Issue date: 2009 Oct
- Subacute cutaneous lupus erythematosus and systemic lupus erythematosus associated with abatacept.
- Authors: Tarazi M, Aiempanakit K, Werth VP
- Issue date: 2018 Aug
- Drug-induced lupus erythematosus.
- Authors: Vedove CD, Del Giglio M, Schena D, Girolomoni G
- Issue date: 2009 Jan
- Using the American College of Rheumatology (ACR) and Systemic Lupus International Collaborating Clinics (SLICC) criteria to determine the diagnosis of systemic lupus erythematosus (SLE) in patients with subacute cutaneous lupus erythematosus (SCLE).
- Authors: Tiao J, Feng R, Carr K, Okawa J, Werth VP
- Issue date: 2016 May
Showing items related by title, author, creator and subject.
A case of "refractory" lupus erythematosus profundus responsive to rituximab [case report].McArdle, Adrian; Baker, Joshua F; St Vincent's University Hospital, Elm Park, Dublin 4, Ireland. (2012-02-01)Lupus erythematosus profundus is a rare complication of systemic lupus erythematosus characterized by the presence of deep, tender subcutaneous nodules. A 22-year-old African-American female with extensive lupus profundus resistant to conventional therapies was treated with two infusions of the anti-CD20 monoclonal antibody, rituximab, at a dosage of 1,000 mg each. The patient demonstrated a remarkable clinical response as indicated by the disappearance of the nodules. B-cell depletion therapy with rituximab used alone or in combination with other therapies may be a viable option in patients with lupus profundus refractory to current therapies.
Photoprotective behaviour and sunscreen use: impact on vitamin D levels in cutaneous lupus erythematosus.Cusack, Caitriona; Danby, Claire; Fallon, Jason C; Ho, Wen Lyn; Murray, Barbara; Brady, Jennifer; O'Kelly, Patrick; Ambrose, Nicola; Kearns, Grainne; Murphy, Gillian M; Department of Dermatology, Beaumont Hospital, Dublin, Ireland. (2008-10)We suggest that patients with cutaneous lupus erythematous have suboptimal 25(OH)D levels, which are significantly raised by the addition of at least 400 IU/day of cholecalciferol. We recommend supplementation with an active vitamin D analogue in collaboration with a consultant nephrologist, for the subgroup of patients with renal disease.